Avidity Biosciences, Inc. Income Statement
RNA / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Avidity Biosciences, Inc. reported $19M in revenue and $685M in net loss for FY2025. Revenue has grown at a 74.6% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.8M | $10.9M | $9.6M | $9.2M | $9.3M | $6.8M | $2.3M | $379.0K |
| SG&A Expense | $205.5M | $86.2M | $54.2M | $37.7M | $26.2M | $13.5M | $5.1M | $2.4M |
| R&D Expense | $559.2M | $303.6M | $191.0M | $150.4M | $101.2M | $37.6M | $14.5M | $8.4M |
| Operating Income | -$745.9M | -$378.9M | -$235.6M | -$178.9M | -$118.1M | -$44.3M | -$17.3M | -$10.5M |
| Interest Expense | - | - | - | $0 | $0 | $209.0K | $7.4M | $718.0K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - |
| Net Income | -$684.6M | -$322.3M | -$212.2M | -$174.0M | -$118.0M | -$44.4M | -$24.7M | -$11.2M |
| EPS (Basic) | -$4.97 | -$2.89 | -$2.91 | -$3.34 | -$2.85 | -$2.05 | - | - |
| EPS (Diluted) | -$4.97 | -$2.89 | -$2.91 | -$3.34 | -$2.85 | -$2.05 | - | - |
| Shares Outstanding | 137.7M | 111.6M | 73.0M | 52.2M | 41.4M | 21.7M | 2.7M | 2.5M |